Talis Biomedical Corp (Talis) develops molecular diagnostic tests for infectious diseases. The company develops talis one system a cloud-enabled molecular diagnostic platform that comprises a compact instrument, single-use test cartridges and software to detect infections related to women’s health, sexually transmitted and respiratory infections. Its talis one COVID-19 test system is used to identify SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2. Talis utilizes its proprietary NAAT (nucleic acid amplification test) technology platform to develop its solutions. The company operates with an additional office in Chicago, California, the US. Talis is headquartered in Redwood City, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Talis Biomedical Corp
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
- Talis Biomedical Corp Company Overview
- Talis Biomedical Corp Company Snapshot
- Talis Biomedical Corp Pipeline Products and Ongoing Clinical Trials Overview
- Talis Biomedical Corp - Pipeline Analysis Overview
- Talis Biomedical Corp - Key Facts
- Talis Biomedical Corp - Major Products and Services
- Talis Biomedical Corp Pipeline Products by Development Stage
- Talis Biomedical Corp Pipeline Products Overview
- CLIA-Waived Molecular Diagnostic Test - Chlamydia And Gonorrhea
- CLIA-Waived Molecular Diagnostic Test - Chlamydia And Gonorrhea Product Overview
- Rapid Phenotypic Antibiotic Susceptibility Test - Gonorrhea
- Rapid Phenotypic Antibiotic Susceptibility Test - Gonorrhea Product Overview
- SlipChip Device
- SlipChip Device Product Overview
- Talis One - Bacterial Vaginosis Assay
- Talis One - Bacterial Vaginosis Assay Product Overview
- Talis One - COVID-19/Influenza A/B Assay
- Talis One - COVID-19/Influenza A/B Assay Product Overview
- Talis One - CT/NG Assay
- Talis One - CT/NG Assay Product Overview
- Talis One - CT/NG/Mgen/Trich Assay
- Talis One - CT/NG/Mgen/Trich Assay Product Overview
- Talis One - CT/NG/TV Assay
- Talis One - CT/NG/TV Assay Product Overview
- Talis One - Group B Streptococcal Infection Assay
- Talis One - Group B Streptococcal Infection Assay Product Overview
- Talis One - Herpes Simplex Virus Assay
- Talis One - Herpes Simplex Virus Assay Product Overview
- Talis One - Urinary Tract Infections Assay
- Talis One - Urinary Tract Infections Assay Product Overview
- Talis Biomedical Corp - Key Competitors
- Talis Biomedical Corp - Key Employees
- Talis Biomedical Corp - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Talis Biomedical Corp, Recent Developments
- Nov 14, 2023: Talis Biomedical Announces Exploration of Strategic Alternatives and Cost Reduction Plan to Preserve Cash
- May 04, 2023: Talis Biomedical to provide business update and financial results on May 11 2023
- Apr 26, 2022: Talis Biomedical to Announce First Quarter 2022 Financial Results on May 10, 2022
- Dec 07, 2021: The Talis One COVID-19 test system is expected to detect the new coronavirus variant omicron
- Nov 08, 2021: Talis Biomedical granted FDA Emergency Use Authorization (EUA) for COVID-19 molecular Point-of-Care Test to detect SARS-CoV-2
- Jul 27, 2021: Talis Biomedical to Announce Second Quarter 2021 Financial Results on August 10, 2021
- May 04, 2021: Talis Biomedical to Announce First Quarter 2021 Financial Results on May 11, 2021
- Apr 28, 2021: Talis Biomedical to Participate in Upcoming BofA Securities 2021 Virtual Healthcare Conference
- Mar 08, 2021: Talis provides update on regulatory pathway for emergency use authorization (EUA) of its Talis One COVID-19 test
- Jul 31, 2020: NIH delivering new COVID-19 testing technologies to meet U.S. demand
- Appendix
- Methodology
- About the Analyst
- Contact the Publisher
- Disclaimer
- Talis Biomedical Corp Pipeline Products and Ongoing Clinical Trials Overview
- Talis Biomedical Corp Pipeline Products by Equipment Type
- Talis Biomedical Corp Pipeline Products by Indication
- Talis Biomedical Corp, Key Facts
- Talis Biomedical Corp, Major Products and Services
- Talis Biomedical Corp Number of Pipeline Products by Development Stage
- Talis Biomedical Corp Pipeline Products Summary by Development Stage
- CLIA-Waived Molecular Diagnostic Test - Chlamydia And Gonorrhea - Product Status
- CLIA-Waived Molecular Diagnostic Test - Chlamydia And Gonorrhea - Product Description
- Rapid Phenotypic Antibiotic Susceptibility Test - Gonorrhea - Product Status
- Rapid Phenotypic Antibiotic Susceptibility Test - Gonorrhea - Product Description
- SlipChip Device - Product Status
- SlipChip Device - Product Description
- Talis One - Bacterial Vaginosis Assay - Product Status
- Talis One - Bacterial Vaginosis Assay - Product Description
- Talis One - COVID-19/Influenza A/B Assay - Product Status
- Talis One - COVID-19/Influenza A/B Assay - Product Description
- Talis One - CT/NG Assay - Product Status
- Talis One - CT/NG Assay - Product Description
- Talis One - CT/NG/Mgen/Trich Assay - Product Status
- Talis One - CT/NG/Mgen/Trich Assay - Product Description
- Talis One - CT/NG/TV Assay - Product Status
- Talis One - CT/NG/TV Assay - Product Description
- Talis One - Group B Streptococcal Infection Assay - Product Status
- Talis One - Group B Streptococcal Infection Assay - Product Description
- Talis One - Herpes Simplex Virus Assay - Product Status
- Talis One - Herpes Simplex Virus Assay - Product Description
- Talis One - Urinary Tract Infections Assay - Product Status
- Talis One - Urinary Tract Infections Assay - Product Description
- Talis Biomedical Corp, Key Employees
- Talis Biomedical Corp, Other Locations
- Glossary
- Talis Biomedical Corp Pipeline Products by Equipment Type
- Talis Biomedical Corp Pipeline Products by Development Stage
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Quest Diagnostics Inc
- Abbott Laboratories
- Laboratory Corp of America Holdings
- BioFire Diagnostics Inc
- Binx Health Inc
